Harvard Apparatus Regenerative Technology, Inc.

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2025	2024	2025	2024
Product revenue	$123	$59	$485	$172
Operating expenses:
Cost of sales	112	70	447	95
Research and development	655	557	1,953	2,039
Sales and marketing	25	143	35	455
General and administrative	1,045	1,148	3,267	3,944
Total operating expenses	1,837	1,918	5,702	6,533
Operating loss	(1,714)	(1,859)	(5,217)	(6,361)
Other income (expense), net:
Interest income	11	10	31	9
Interest expense	(2)	(11)	(7)	(36)
Other income	5	—	11	—
Other income (expense), net	14	(1)	35	(27)
Net loss	$(1,700)	$(1,860)	$(5,182)	$(6,388)
Basic and diluted net loss per share	$(0.10)	$(0.12)	$(0.32)	$(0.44)
Weighted average common shares outstanding, basic and diluted	17,033,109	15,017,591	16,294,437	14,410,034
Comprehensive loss:
Net loss	$(1,700)	$(1,860)	$(5,182)	$(6,388)
Foreign currency translation adjustments	(2)	(2)	(3)	(24)
Comprehensive loss	$(1,702)	$(1,862)	$(5,185)	$(6,412)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.